EUVIMEDEUVIMED entdecken
Open Access

Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia

Nicholas J Short, Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall, Amber Gibson, Nitin Jain, Fadi G Haddad, Lewis F Nasr, Kayleigh R Marx, Caitlin Rausch und 4 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2023.12.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Nicholas J Short und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: nshort@mdanderson.org. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antibodies, Bispecific, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Cardiovascular Diseases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The combination of low-intensity chemotherapy and inotuzumab ozogamicin (INO), with sequential blinatumomab, is highly effective in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) and in relapsed or refractory B-cell ALL. Earlier, "dose-dense" administration of blinatumomab could lead to earlier and deeper measurable residual disease (MRD) responses and better outcomes. PATIENTS AND METHODS: We performed a retrospective analysis of the safety and efficacy of a dose-dense regimen of mini-hyper-CVD (mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone alternating with mini-methotrexate and cytarabine), INO, and blinatumomab in patients with B-cell ALL. RESULTS: Twenty-one patients were treated (frontline, n = 9; MRD consolidation, n = 4; relapsed/refractory, n = 8). In the frontline cohort, all patients achieved CR/CRi and MRD negativity by flow cytometry at the end of cycle 1. Across the frontline and MRD consolidation cohorts, 10/11 patients (91%) achieved next-generation sequencing MRD negativity at a sensitivity of 10-6, including 6/10 evaluable patients (60%) who achieved next-generation sequencing MRD negativity after cycle 1. The CR/CRi rate in the relapsed/refractory cohort was 63%, and all responders achieved MRD negativity by flow cytometry at the end of cycle 1. The 1-year overall survival rate for the combined cohort of the frontline and MRD-positive patients was 83%. No new safety signals were observed with the dose-dense mini-hyper-CVD, INO, and blinatumomab regimen. CONCLUSION: Dose-dense delivery of mini-hyper-CVD, INO, and blinatumomab was safe and resulted in rapid and deep MRD negativity in patients with B-cell ALL. This regimen is now being prospectively evaluated in both the frontline and relapsed/refractory settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaAntibodies, BispecificPrecursor B-Cell Lymphoblastic Leukemia-LymphomaCardiovascular DiseasesHumansAgedInotuzumab OzogamicinRetrospective StudiesPhiladelphia Chromosome

Stichwörter der Autor:innen

Antibody-drug conjugateBispecific antibodyCD19CD22Chemoimmunotherapy

Substanzen

Inotuzumab OzogamicinblinatumomabAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: nshort@mdanderson.org.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • National Cancer Institute
  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Short, N. J., Jabbour, E., Jamison, T., Paul, S., Cuglievan, B., McCall, D., Gibson, A., Jain, N., Haddad, F. G., Nasr, L. F., Marx, K. R., Rausch, C., Savoy, J. M., Garris, R., Ravandi, F., & Kantarjian, H. (2024). Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.12.016

Vancouver

Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, et al. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.12.016

BibTeX
@article{Short2024,
  author = {Short, Nicholas J and Jabbour, Elias and Jamison, Trevor and Paul, Shilpa and Cuglievan, Branko and McCall, David and Gibson, Amber and Jain, Nitin and Haddad, Fadi G and Nasr, Lewis F and Marx, Kayleigh R and Rausch, Caitlin and Savoy, J Michael and Garris, Rebecca and Ravandi, Farhad and Kantarjian, Hagop},
  title = {Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2023.12.016}
}
Kostenlos starten →